1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
AnGes, Inc.

AnGes, Inc.

AMGXF
AnGes, Inc.US flagOther OTC
0.36
USD
- -
- -
142.50MMarket Cap
AnGes, Inc.
AMGXF
(Other OTC)

Recent

price

0.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.31
8.48
14.93
16.35
23.86
7.74
8.11
4.79
7.02
3.12
0.34
0.44
0.43
0.81
2.74
2.46
2.25
Revenue per Share
-70.66
-63.25
-57.37
-46.91
-62.12
-74.53
-75.29
-49.38
-34.46
-35.81
-35.33
-92.86
-94.29
-39.29
-119.53
-14.44
-30.61
Basic EPS, GAAP
-67.91
-62.35
-55.52
-48.96
-71.37
-83.87
-79.67
-39.36
-29.59
-20.88
-25.53
-77.82
-71.99
-46.67
-28.43
-16.25
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-131.42
-184.25
-228.38
-216.47
-146.32
-168.29
-184.36
25.89
31.22
27.28
83.66
142.08
51.24
88.05
-39.34
-32.16
70.68
Book Value per Share
148.37
109.04
54.94
115.59
201.37
75.01
60.12
47.51
88.94
115.11
83.64
108.36
45.95
23.02
9.12
8.65
12.7
Tangible Book Value per Share
28
29
30
30
38
56
63
76
87
105
119
147
156
189
235
355
200
Basic Weighted Avg Shares
287
243
445
491
910
430
514
365
610
327
40
64
67
153
644
874
449
Sales/Revenue/Turnover
-700.67
-863.1
-401.65
-277.45
-249.9
-969.88
-926.24
-900.56
-502.46
-1,000.74
-13,999.18
-24,369.16
-24,331.65
-7,822.66
-1,415.31
-588.64
-2,475.71
Operating Margin (%)
102
109
93
60
46
49
67
29
8
7
8
2,426
2,902
3,109
3,372
54
- -
Depreciation Expense
-1,967
-1,815
-1,708
-1,410
-2,369
-4,143
-4,777
-3,765
-2,997
-3,751
-4,210
-13,676
-14,715
-7,438
-28,129
-5,123
-6,108
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
42.64
Effective Tax Rate (%)
-685.64
-745.74
-384.33
-286.92
-260.37
-963.22
-928.85
-1,030.91
-491.21
-1,147.89
-10,524.3
-21,319.14
-21,942.7
-4,861.66
-4,370.31
-586.11
-1,359.35
Profit Margin (%)
3,426
2,034
836
2,959
7,171
3,761
2,989
3,116
7,251
10,549
8,577
14,693
5,573
3,428
1,229
2,143
1,662
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
995
215
109
- -
174
LT Debt
4,288
3,271
1,739
3,544
7,734
4,221
3,869
3,622
7,734
12,055
32,680
38,635
30,425
26,103
2,157
3,076
25,477
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-60.1
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-127.84
-134.63
-65.64
-88.54
-101.76
-60.31
- -
- -
-37.15
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
148
155
162
LT Borrowings
- -
- -
- -
LT Finance Leases
215
197
174
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
198
201
237
Market Capitalization
- -
13,914
10,414

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
5,921
4,393
3,591
Cash, Cash Equivalents & STI
4,160
2,116
1,821
Accounts Receivable, Net
27
98
200
Inventories
1,566
1,939
1,303
Total Current Liabilities
2,493
2,690
1,929
Payables & Accruals
- -
- -
- -
ST Debt
148
155
162
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.94%
-13.27%
42.64%
Free Cash Flow
19.29%
43.05%
-13.84%
Net Income, GAAP
39.05%
75.89%
-81.79%
Sales/Revenue/Turnover
47.3%
109.92%
35.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
114
234
- -
- -
644
2025
- -
- -
- -
- -
874
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-9.14
- -
- -
- -
-119.53
2025
- -
- -
- -
- -
-14.44
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Amniotics AB (publ) (AMNI.ST)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Chiasma, Inc. (CHMA)
argenx SE (0QW0.L)
Kadimastem Ltd (KDST.TA)
GC Corp. (005250.KS)
Business
AnGes, Inc. is a Japanese biopharmaceutical company specializing in the research, development, and marketing of gene-based medicines and gene therapy products. Its core products include hepatocyte growth factor (HGF) gene therapy for ischemic diseases such as chronic arterial occlusive disease; NF-κB decoy oligonucleotides for chronic discogenic lumbar back pain; DNA vaccines; and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vectors. The company also develops genome editing technology platforms and products through its consolidated subsidiary EmendoBio Inc., expanding its capabilities in advanced gene therapy. AnGes operates primarily in Japan, the United States, and other international markets, supported by subsidiaries including AnGes USA, Inc. and EmendoBio Inc., both headquartered in Jersey City, New Jersey. Founded in December 1999 and headquartered in Ibaraki, Japan, AnGes focuses its business segments on nucleic acid medicine and genomic drug discovery targeting intractable, rare diseases, and diseases lacking effective treatments. Recent major developments include the FDA granting Breakthrough Therapy designation in 2024 for its flagship HGF gene therapy product. The company is actively developing a Tie2 tyrosine kinase receptor agonist (AV-001) for viral and bacterial-associated pneumonia and continuing advancement of NF-κB decoy oligonucleotide treatments. Strategic expansions include the acquisition of EmendoBio Inc. in December 2020 to strengthen genome editing technology and the establishment of new R&D bases, including in the U.S. Additionally, AnGes has engaged in strategic alliances, such as co-development partnerships with Vasomune Therapeutics for COVID-19/ARDS therapeutics and MyBiotics Pharma for microbiome-related treatments. These initiatives underscore AnGes' commitment to advancing innovative gene-based medicines for global markets.